Continuous Ketone Monitoring Market (2026-2036)
The global Continuous Ketone Monitoring Market was valued at USD 18.5 million in 2025. This market is expected to reach USD 5,484.6 million by 2036 from an estimated USD 118.0 million in 2026, registering a CAGR of 46.8% during the forecast period (2026-2036).
- Published
- Oct 2026
- Pages
- 327
- Format
- PDF + Excel
- Report ID
- MR-2258
- Base year
- 2025
- 2025 · BASELINE
- $18.5M
- 2036
- $5.48B
- CAGR 2026–2036
- 46.8%
2025 baseline · 2026–2036 forecast at 46.8% CAGR · hover a bar for the value
Key highlights
The global Continuous Ketone Monitoring Market is projected to reach USD 5, 484.6 million by 2036, driven by the burden of diabetic ketoacidosis, SGLT2 inhibitor use, and the first regulatory authorizations for continuous ketone sensing.
North America is expected to account for the largest market share in 2026, while Asia-Pacific is projected to register the fastest growth during the forecast period.
The first continuous ketone monitors have been authorized. Abbott received CE marking for its Libre Duo and Libre Duo 10 Day dual glucose-ketone sensors in May 2026, and on 25 August 2026 the U.S. FDA granted De Novo authorization to Libre Duo 10 Day, the first wearable in the U.S. to continuously monitor ketones and the first system to meet the FDA's new integrated continuous glucose and ketone monitoring (iCGK) standard.
By product type, Dual Glucose-Ketone Sensors are expected to account for the largest market share, whereas Software & Data Platforms are projected to witness the fastest growth through 2036.
Diabetic ketoacidosis remains a growing burden. Abbott cited data showing that hospital admissions for diabetic ketoacidosis have increased by 55% over the past decade, and noted that most people with diabetes do not have a blood ketone meter at home.
Clinical consensus is forming. The first international consensus framework for continuous ketone monitoring, published in The Lancet Diabetes & Endocrinology in December 2025, described ketone sensors for the prevention of diabetic ketoacidosis as transformational, and consensus recommendations endorsed by the International Society for Pediatric and Adolescent Diabetes were published in 2026.
Report summary
| Particulars | Details |
|---|---|
| Forecast Period | 2026-2036 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| CAGR (Value) | 46.8% |
| Format | PDF, Excel & Cloud Portal · 327 pages |
| Market Size (Value) in 2026 | USD 118.0 Million |
| Market Size (Value) in 2036 | USD 5,484.6 Million |
| Segments Covered | By Product Type: Dual Glucose-Ketone Sensors, Standalone Ketone Sensors, Software & Data Platforms. By Integration: Standalone Systems, Systems Integrated with Automated Insulin Delivery. By Wear Duration: Up to 10 Days, More than 10 Days. By Patient Population: Type 1 Diabetes, Insulin-Treated Type 2 Diabetes, SGLT2 Inhibitor Users, Pregnancy, Other High-Risk Populations. By Age Group: Pediatric, Adult. By End User: Home Care Settings, Hospitals & Clinics, Research Institutions. By Distribution Channel: Retail Pharmacies, Durable Medical Equipment Suppliers, Online & Direct-to-Consumer. |
| Countries Covered | North America: U.S., Canada. Europe: Germany, U.K., France, Netherlands, Italy, Spain, Nordic Countries, Rest of Europe. Asia-Pacific: China, Japan, India, South Korea, Australia, Rest of Asia-Pacific. Latin America: Brazil, Mexico, Argentina, Colombia, Chile, Rest of Latin America. Middle East & Africa: Saudi Arabia, UAE, Kuwait & Qatar, Israel, South Africa, Rest of Middle East & Africa. |
| Key Companies | Abbott Laboratories, Dexcom, MiniMed, Roche Diabetes Care, Senseonics, Insulet, Tandem Diabetes Care, Ypsomed, SiBionics, Sinocare, Medtrum, i-SENS, PercuSense, and Biolinq. |
Report overview
Segments covered: product type, integration, wear duration, patient population, age group, end user, distribution channel.
The growth of this market is mainly driven by the rising burden of diabetic ketoacidosis, the growing use of SGLT2 inhibitors and the associated risk of euglycemic ketoacidosis, and the first regulatory authorizations and clinical consensus for continuous ketone monitoring. However, the limited number of authorized products, uncertain reimbursement for a new device category, technical limitations of early sensors, and quality and reliability risks in continuous sensing restrain the growth of this market.
Furthermore, integration with automated insulin delivery systems, hospital and perioperative ketone monitoring, and applications beyond routine diabetes care are expected to offer growth opportunities for the stakeholders in this market. However, defining clinical thresholds and response protocols, achieving interoperability with insulin delivery systems, manufacturing dual-analyte sensors reliably at scale, and demonstrating outcome benefits and cost-effectiveness remain major challenges impacting the growth of this market. Additionally, the convergence of glucose and ketone sensing in multi-analyte biowearables, the formation of standards and consensus for ketone monitoring, the integration of ketone data into connected diabetes ecosystems, and the expansion of SGLT2 inhibitor use in type 1 diabetes are prominent trends in this market.
The Continuous Ketone Monitoring Market comprises wearable sensors and associated software that continuously measure ketone levels, principally beta-hydroxybutyrate, the predominant ketone in diabetic ketoacidosis (DKA), in interstitial fluid, together with readers, smartphone applications, alerts, and data platforms used by patients, caregivers, and clinicians. The market covers dual glucose-ketone sensors that measure both analytes from a single wearable, standalone ketone sensors, and software and data services, used primarily by people with type 1 diabetes, people with type 2 diabetes treated with insulin, and people taking sodium-glucose cotransporter-2 (SGLT2) inhibitors, as well as other high-risk groups such as pregnant women with diabetes and hospitalized patients. Traditional blood ketone meters and urine ketone strips are excluded. The ecosystem spans continuous glucose monitoring manufacturers, insulin pump and automated insulin delivery (AID) companies, sensor technology developers, digital health platforms, clinicians, diabetes educators, pharmacists, and payers.
The market is at the beginning of commercialization. Abbott received CE marking in May 2026 for Libre Duo, for adults aged 18 and older with up to 15 days of wear, and Libre Duo 10 Day, for people aged 2 and older, both measuring glucose and ketones every minute, and planned a phased rollout in select European countries later in 2026. On 25 August 2026, the U.S. FDA granted De Novo authorization to Libre Duo 10 Day following breakthrough device designation, on the basis of six clinical studies enrolling more than 600 participants aged 2 and older; it became the first system to meet both the FDA's integrated continuous glucose monitoring (iCGM) standard and its new integrated continuous glucose and ketone monitoring (iCGK) standard, and Abbott planned a U.S. launch later in 2026. Abbott and MiniMed are collaborating on an exclusive integration of Abbott's dual glucose-ketone sensors with MiniMed automated insulin delivery systems, expected in 2027.
The clinical need is significant. Diabetic ketoacidosis can develop within hours when insulin is insufficient, and Abbott has cited data showing a 55% increase in DKA hospital admissions over the past decade. Existing tools are limited: urine ketone strips measure acetoacetate rather than beta-hydroxybutyrate, degrade in humid conditions, and do not reflect real-time blood levels, while most people with diabetes do not have a blood ketone meter at home, and early symptoms of rising ketones are often mistaken for common infections. The risk is heightened with SGLT2 inhibitors, which can cause euglycemic DKA with normal or only mildly elevated glucose; the FDA issued a safety communication on this risk in May 2015 after identifying 20 cases requiring emergency care or hospitalization.
Clinical frameworks are emerging alongside the technology. The first international consensus on continuous ketone monitoring was published in The Lancet Diabetes & Endocrinology in December 2025, and consensus recommendations endorsed by the International Society for Pediatric and Adolescent Diabetes (ISPAD) followed in 2026, describing continuous ketone monitoring as an emerging safety technology with structured alert thresholds for clinical action. However, clinicians have limited experience interpreting continuous ketone data, Abbott cautions that its Urgent High Ketones alarm may not detect all instances of ketones above 3.0 mmol/L, and adoption will depend on reimbursement, integration with insulin delivery systems, and evidence of reduced DKA.
Market dynamics
18 factors across 5 forcesRising Burden of Diabetic Ketoacidosis
The rising burden of diabetic ketoacidosis is a major factor driving the Continuous Ketone Monitoring Market. DKA is a life-threatening emergency that develops when the body lacks sufficient insulin and breaks down fat for energy, causing ketones to accumulate, and it can progress within hours. Abbott has cited data showing that hospital admissions for DKA have increased by 55% over the past decade. Current detection methods are inadequate: urine ketone strips measure acetoacetate rather than beta-hydroxybutyrate, the predominant ketone in DKA, degrade quickly in humid environments, and fail to reflect real-time levels, while most people with diabetes do not have a blood ketone meter at home, and early symptoms are frequently mistaken for common infections. Continuous monitoring that alerts patients and caregivers to rising ketones before symptoms become severe addresses this gap, and even modest reductions in DKA hospitalizations could generate substantial savings for health systems, creating strong clinical and economic demand for continuous ketone sensors. Abbott's Libre Duo 10 Day, authorized by the FDA on 25 August 2026 for people aged 2 and older, was evaluated in six clinical studies enrolling more than 600 participants and was shown to identify elevated ketones before the onset of DKA, demonstrating that continuous measurement can provide the early warning that intermittent blood and urine tests often fail to deliver.
Growing Use of SGLT2 Inhibitors and Risk of Euglycemic Ketoacidosis
The growing use of SGLT2 inhibitors and the associated risk of euglycemic DKA are significantly increasing the need for ketone monitoring. SGLT2 inhibitors are widely prescribed for type 2 diabetes, heart failure, and chronic kidney disease because of their cardiovascular and kidney benefits, but they can precipitate DKA with normal or only mildly elevated glucose levels, which glucose monitoring alone cannot detect. The FDA issued a Drug Safety Communication in May 2015 warning of this risk after identifying 20 cases requiring emergency treatment or hospitalization between March 2013 and June 2014. Clinicians are increasingly interested in using SGLT2 inhibitors, even at reduced doses, in people with type 1 diabetes for their cardiorenal protection, but the elevated risk of euglycemic DKA has limited this use. Abbott positions its Libre Duo 10 Day system for people at higher risk of elevated ketones, including those using insulin or SGLT2 inhibitors, making this population a key target for continuous ketone monitoring.
First Regulatory Authorizations and Clinical Consensus
The first regulatory authorizations and clinical consensus for continuous ketone monitoring are creating the foundation for market adoption. Abbott received CE marking for Libre Duo and Libre Duo 10 Day in May 2026, and the U.S. FDA granted De Novo authorization to Libre Duo 10 Day on 25 August 2026 after breakthrough device designation, establishing a new integrated continuous glucose and ketone monitoring (iCGK) standard that will serve as a benchmark for future products. The FDA's authorization was based on six clinical studies enrolling more than 600 participants aged 2 and older, which showed that the device accurately tracked clinically meaningful changes in ketone levels and identified elevated ketones before the onset of DKA. In parallel, the first international consensus framework on continuous ketone monitoring was published in The Lancet Diabetes & Endocrinology in December 2025, and ISPAD-endorsed recommendations followed in 2026. These milestones give clinicians, payers, and competitors a clear regulatory and clinical pathway.
Table of contents
15 chapters · 154 sections · 327 pages · click to expandSegmental analysis
| Segment | Largest share (2026) | Fastest growth (2026–2036) |
|---|---|---|
| By Product Type | Dual Glucose-Ketone Sensors | Software & Data Platforms |
| By Integration | — | Rapid growth of this |
| By Patient Population | Type 1 Diabetes | SGLT2 Inhibitor Users |
| By Age Group | — | Rapid growth of this |
| By End User | Home Care Settings | Hospitals & Clinics |
By Product Type
- The Dual Glucose-Ketone Sensors segment is expected to account for the largest share of the market.
- The large share of this segment is mainly due to the authorization of Abbott's Libre Duo systems in Europe and the U.S. and the convenience of measuring both analytes with a single wearable.
- However, the Software & Data Platforms segment is projected to register the highest CAGR during the forecast period.
- The rapid growth of this segment is attributed to remote monitoring, clinical decision support, and integration of ketone data with insulin delivery systems and electronic health records.
By Integration
- The Standalone Systems segment is expected to account for the larger share of the market.
- The large share of this segment is mainly due to the initial launch of continuous ketone monitoring as a standalone app-based system before pump integrations become available.
- However, the Systems Integrated with Automated Insulin Delivery segment is projected to register the higher CAGR during the forecast period.
- The rapid growth of this segment is attributed to the planned integration of Abbott's dual sensors with MiniMed systems in 2027 and the high DKA risk associated with insulin delivery failures.
By Patient Population
- The Type 1 Diabetes segment is expected to account for the largest share of the market.
- The large share of this segment is mainly due to the high risk of DKA in people with type 1 diabetes and their established use of continuous glucose monitoring.
- However, the SGLT2 Inhibitor Users segment is projected to register the highest CAGR during the forecast period.
- The rapid growth of this segment is attributed to the widespread use of SGLT2 inhibitors for diabetes, heart failure, and kidney disease and the inability of glucose monitoring to detect euglycemic DKA.
By Age Group
- The Adult segment is expected to account for the larger share of the market.
- The large share of this segment is mainly due to the larger adult population with type 1 and insulin-treated type 2 diabetes and the availability of both Libre Duo systems for adults.
- However, the Pediatric segment is projected to register the higher CAGR during the forecast period.
- The rapid growth of this segment is attributed to the authorization of Libre Duo 10 Day for children aged 2 and older, the high risk of DKA in children, and the widespread use of insulin pumps among newly diagnosed pediatric patients.
By End User
- Market Analysis by End User and Distribution Channel
- The Home Care Settings segment is expected to account for the largest share of the market.
- The large share of this segment is mainly due to the design of continuous ketone monitors for self-management and caregiver monitoring at home.
- However, the Hospitals & Clinics segment is projected to register the highest CAGR during the forecast period.
- The rapid growth of this segment is attributed to growing interest in inpatient, perioperative, and emergency ketone monitoring.
Geographic analysis
North America
Largest shareIn 2026, North America is expected to account for the largest share of the global Continuous Ketone Monitoring Market. The region's dominance is supported by high adoption of continuous glucose monitoring and automated insulin delivery, a large population with type 1 diabetes, and the first U.S. authorization of a continuous ketone monitor. The U.S. FDA granted De Novo authorization to Abbott's Libre Duo 10 Day on 25 August 2026, establishing the new iCGK standard, and Abbott planned a U.S. launch later in 2026, with integration into MiniMed automated insulin delivery systems expected in 2027. Abbott has cited a 55% increase in DKA hospital admissions over the past decade, and widespread use of SGLT2 inhibitors, subject to the FDA's 2015 safety communication and 2020 labeling on stopping these drugs before surgery, creates a large at-risk population. Canada's advanced diabetes care and high continuous glucose monitoring use also support adoption. North America
Europe
Europe is expected to account for a significant share of the market and was the first region to authorize continuous ketone monitoring. Abbott received CE marking for Libre Duo, for adults aged 18 and older with up to 15 days of wear, and Libre Duo 10 Day, for people aged 2 and older, in May 2026, and planned a phased rollout in select European countries later in 2026. The approval indicated that EU Medical Device Regulation pathways can accommodate novel multi-analyte monitoring when supported by clinical accuracy data. European health systems in the U.K., Germany, France, the Netherlands, and the Nordic countries provide broad reimbursement for continuous glucose monitoring for people with type 1 diabetes, creating a base for reimbursement of dual sensors, and European clinicians contributed to the international consensus on continuous ketone monitoring published in December 2025. Europe
Asia-Pacific
Fastest growthHowever, Asia-Pacific is projected to register the highest CAGR during the forecast period. The rapid growth of this region is attributed to its very large population with diabetes, rising use of continuous glucose monitoring, and a strong base of regional sensor manufacturers. India's national diabetes study estimated that 101 million people were living with diabetes in 2021, China has a large and growing domestic continuous glucose monitoring industry, including companies such as SiBionics, Sinocare, and Medtrum, and South Korea's i-SENS is developing continuous sensing products. Japan and Australia have well-developed diabetes care systems and public support for continuous glucose monitoring in type 1 diabetes, and SGLT2 inhibitors are widely prescribed across the region, supporting future adoption once continuous ketone monitors are authorized. Asia-Pacific
Latin America
Latin America is expected to account for a smaller share of the market, but has a large and growing population with diabetes, with the International Diabetes Federation estimating that about 32 million adults in South and Central America were living with diabetes in 2021. Brazil and Mexico have significant numbers of people with type 1 and insulin-treated type 2 diabetes, and continuous glucose monitoring use is growing through private insurance and self-pay channels, providing an entry point for dual glucose-ketone sensors once regulatory approvals are obtained. Access to blood ketone testing is limited in many parts of the region, increasing the potential value of continuous monitoring for DKA prevention, particularly among children. Brazil's General Data Protection Law, with fines of up to 2% of revenue in Brazil capped at BRL 50 million per infraction, governs the connected health data generated by these devices, and Argentina, Colombia, and Chile have active diabetes care networks. Latin America
Middle East & Africa
The Middle East & Africa is expected to register strong growth from a small base. The International Diabetes Federation estimated that about 73 million adults in the Middle East and North Africa were living with diabetes in 2021, one of the highest regional prevalence rates in the world, and Gulf countries such as Saudi Arabia, the UAE, Kuwait, and Qatar have well-funded healthcare systems and growing adoption of continuous glucose monitoring. SGLT2 inhibitors are widely used in the region for type 2 diabetes and cardiorenal disease, and fasting during Ramadan increases the risk of ketoacidosis for some people with diabetes, highlighting the potential value of continuous ketone monitoring. Saudi Arabia's Personal Data Protection Law, enforced since September 2024, governs connected health data, and South Africa and Israel have established diabetes technology markets. Middle East & Africa
Competitive landscape
The global Continuous Ketone Monitoring Market is at an early stage, with Abbott the first and, as of September 2026, the only company with authorized continuous ketone monitoring products in the U.S. and Europe. Other continuous glucose monitoring manufacturers, insulin pump and automated insulin delivery companies, and specialized sensor developers have reported programs or partnerships in continuous ketone sensing. Competition is expected to center on sensor accuracy across glucose and ketone ranges, wear duration, alarm performance, integration with insulin delivery systems and digital platforms, pricing, and reimbursement.
Leading companies are pursuing dual-analyte sensors, partnerships for automated insulin delivery integration, clinical studies to demonstrate accuracy and outcomes, and regulatory submissions under the FDA's new iCGK standard. The exclusive Abbott and MiniMed integration planned for 2027 illustrates the strategic importance of sensor and pump alliances.
The report provides a comprehensive competitive assessment of the leading companies operating in the global Continuous Ketone Monitoring Market. The key players profiled in the report include Abbott Laboratories (U.S.), Dexcom, Inc. (U.S.), MiniMed (U.S.), Roche Diabetes Care (Switzerland), Senseonics Holdings, Inc. (U.S.), Insulet Corporation (U.S.), Tandem Diabetes Care, Inc. (U.S.), Ypsomed AG (Switzerland), SiBionics Technology Co., Ltd. (China), Sinocare Inc. (China), Medtrum Technologies Inc. (China), i-SENS, Inc. (South Korea), PercuSense, Inc. (U.S.), and Biolinq Incorporated (U.S.).
- Abbott Laboratories
- Dexcom
- MiniMed
- Roche Diabetes Care
- Senseonics
- Insulet
- Tandem Diabetes Care
- Ypsomed
- SiBionics
- Sinocare
- Medtrum
- PercuSense
- Biolinq
Expert perspectives
Continuous ketone monitoring is the first major new analyte in continuous diabetes monitoring since glucose. With Abbott's CE marking in May 2026 and FDA De Novo authorization on 25 August 2026, a new iCGK standard, and international consensus published in December 2025, the market has moved from research to commercialization in less than a year. Its value lies in prevention: detecting rising ketones before DKA, a condition that Abbott says has driven a 55% increase in hospital admissions over the past decade.
Three structural changes are expected to shape the market through 2036. First, dual glucose-ketone sensing will become a standard option within continuous glucose monitoring portfolios, particularly for type 1 diabetes, children, and SGLT2 inhibitor users, as competitors enter under the iCGK standard. Second, integration with automated insulin delivery, starting with the Abbott and MiniMed integration in 2027, will make ketone data part of closed-loop safety systems. Third, reimbursement will follow evidence that continuous ketone monitoring reduces DKA admissions, making outcome studies a key competitive asset.
For companies planning entry or expansion, the most attractive positions over the forecast period are likely to be found in dual-analyte sensors meeting the iCGK standard, automated insulin delivery integration, hospital and perioperative ketone monitoring, and data platforms that turn ketone alerts into clinical action. The principal risks are dependence on a single early supplier, reimbursement uncertainty, sensor performance limitations, and the need to prove outcome benefits.
Customer perspectives
Insights gathered during primary interviews with pediatric endocrinologists, diabetes educators, hospital pharmacists, and payers highlight where purchasing priorities are shifting. The following perspectives reflect recurring themes raised across these discussions.
“This reflects strong clinical demand for continuous ketone monitoring integrated with insulin delivery in pediatrics.”
“This indicates that clinical protocols and education are key to adoption.”
“This points to outcome evidence as the decisive factor for reimbursement.”
Frequently asked questions
The global Continuous Ketone Monitoring Market is estimated at USD 118.0 million in 2026, the first year of commercial launches in Europe and the U.S.
Cite this report
Meticulous Research. (2026). Continuous Ketone Monitoring Market - Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MR-2258). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/continuous-ketone-monitoring-market-6941